Aviragen Therapeutics (AVIR) Tops Q3 EPS by 6c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics